Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria

Trial Profile

Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2014

At a glance

  • Drugs Bilastine (Primary) ; Levocetirizine
  • Indications Urticaria
  • Focus Registrational; Therapeutic Use
  • Sponsors FAES Farma
  • Most Recent Events

    • 17 Jun 2014 New trial record
    • 14 Dec 2007
    • 19 Jul 2007
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top